Clinical trials: Compensated Chronic Hepatitis B
- Condition Compensated Chronic Hepatitis B
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hepatitis B, Chronic
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC).
- Trial name
- NCT02224456
- Testing
- Tenofovir disoproxil fumarate
- Where
- 19 sites in China
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Hepatitis B Virus
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD) taken together vs.
- Trial name
- NCT00805675
- Testing
- Telbivudine, Tenofovir, Telbivudine plus tenofovir
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis B
Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients
This study is designed to compare the efficacy and safety of adefovir dipivoxil 10 mg with lamivudine 100 mg in Japanese patients with compensated chronic hepatitis B over 52-week periods.
- Trial name
- NCT00316719
- Testing
- LAM group, ADV group
- Volunteers
- 105 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic Hepatitis B
Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
This exploratory study is designed to determine the early viral kinetic profile during treatment with telbivudine or entecavir at multiple time points over 12 weeks.
- Trial name
- NCT00412529
- Testing
- Entecavir, Telbivudine
- Where
- 8 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs
The purpose of this study is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in Japanese patients with compensated chronic hepatitis B with poor response to other drugs.
- Trial name
- NCT01475851
- Testing
- GSK548470 300 mg tablet
- Where
- 11 sites in Japan
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients
This 48-week open-label study of local manufactured adefovir dipivoxil Tablet evaluates the efficacy and safety of adefovir 10mg once daily in Chinese subjects with compensated CHB.
- Trial name
- NCT00441974
- Testing
- adefovir dipivoxil
- Where
- 25 sites in China
- Volunteers
- 1,470 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
The purpose of the study was to assess the efficacy and safety of telbivudine at a dose of 20 mg/kg up to a maximum of 600 mg q.d.
- Trial name
- NCT02058108
- Testing
- Telbivudine
- Where
- 29 sites in Bulgaria, Greece and 5 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue
The purpose of this study is to evaluate the efficacy and safety of GSK548470 administered once daily at a dose level of 300 mg to Japanese patients with compensated chronic hepatitis B untreated with any nucleic acid analogue.
- Trial name
- NCT01480284
- Testing
- GSK548470 300 mg tablet, ETV 0.5 mg capsule
- Where
- 32 sites in Japan
- Volunteers
- 166 people
- Sponsor
- GlaxoSmithKline